Ryan Owen

3.3k total citations · 2 hit papers
35 papers, 2.4k citations indexed

About

Ryan Owen is a scholar working on Physiology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ryan Owen has authored 35 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Physiology, 8 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ryan Owen's work include Asthma and respiratory diseases (12 papers), Allergic Rhinitis and Sensitization (6 papers) and Adenosine and Purinergic Signaling (6 papers). Ryan Owen is often cited by papers focused on Asthma and respiratory diseases (12 papers), Allergic Rhinitis and Sensitization (6 papers) and Adenosine and Purinergic Signaling (6 papers). Ryan Owen collaborates with scholars based in United States, United Kingdom and France. Ryan Owen's co-authors include Kathleen M. Giacomini, Jennifer H. Gray, Russ B. Altman, Teri E. Klein, Steven A. Sheardown, Chaline Brown, Joan C. Lo, Yan Shu, Alexandra G. Ianculescu and Esteban G. Burchard and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Ryan Owen

33 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

2007 711 citations Ryan Owen, Kathleen M. Giacomini et al. profile →
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials

2020 453 citations Philippe Gevaert, Theodore A. Omachi et al. Journal of Allergy and Clinical Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ryan Owen United States	17	719	536	535	488	388	35	2.4k
Shigeki Nakagawa Japan	38	1.7k 2.3×	52 0.1×	1.8k 3.5×	426 0.9×	1.2k 3.0×	184	4.9k
Masahiro Tsuda Japan	28	1.1k 1.5×	159 0.3×	1.5k 2.8×	215 0.4×	661 1.7×	127	3.5k
Katherine J. Kelly United States	29	1.2k 1.7×	130 0.2×	162 0.3×	214 0.4×	578 1.5×	54	3.8k
Marie‐Luise Brennan United States	17	758 1.1×	105 0.2×	259 0.5×	837 1.7×	661 1.7×	28	3.4k
Aili L. Lazaar United States	30	827 1.2×	248 0.5×	355 0.7×	929 1.9×	145 0.4×	52	3.0k
Tuva B. Dahl Norway	23	680 0.9×	44 0.1×	235 0.4×	448 0.9×	277 0.7×	67	2.1k
Tsutomu Sakuma Japan	32	705 1.0×	27 0.1×	460 0.9×	176 0.4×	418 1.1×	171	2.9k
Tetsuya Shiomi Japan	23	1.0k 1.5×	127 0.2×	195 0.4×	662 1.4×	487 1.3×	50	2.9k
Thomas C. Wascher Austria	32	972 1.4×	51 0.1×	333 0.6×	731 1.5×	383 1.0×	112	3.0k
Tomomi Fujisawa Japan	33	1.0k 1.4×	53 0.1×	672 1.3×	628 1.3×	867 2.2×	169	3.9k

Countries citing papers authored by Ryan Owen

Since Specialization

Citations

This map shows the geographic impact of Ryan Owen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan Owen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan Owen more than expected).

Fields of papers citing papers by Ryan Owen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan Owen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan Owen. The network helps show where Ryan Owen may publish in the future.

Co-authorship network of co-authors of Ryan Owen

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan Owen. A scholar is included among the top collaborators of Ryan Owen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan Owen. Ryan Owen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ma, Fang, Yoen‐Ju Son, Tom De Bruyn, et al.. (2025). Mechanistic Physiologically Based Pharmacokinetic Modeling of Dry Powder and Nebulized Formulations of Orally Inhaled TMEM16A Potentiator GDC‐6988. CPT Pharmacometrics & Systems Pharmacology. 14(6). 1087–1097.

Zhu, Rui, Rik C. Schoemaker, Xianbin Tian, et al.. (2024). Model‐based comparisons of post‐treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European Union. British Journal of Clinical Pharmacology. 90(12). 3190–3200. 1 indexed citations

Becker, Benjamin, et al.. (2023). A nontraditional presentation and treatment for emphysematous cystitis. Urology Case Reports. 46. 102321–102321. 5 indexed citations

Yu, Yanke, Michael E. Rothenberg, Han Ting Ding, et al.. (2023). Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc). Journal of Pharmacokinetics and Pharmacodynamics. 51(2). 141–153. 2 indexed citations

Zhu, Rui, et al.. (2023). Population-Based Pharmacodynamic Modeling of Omalizumab in Pediatric Patients with Moderate to Severe Persistent Inadequately Controlled Allergic Asthma. The AAPS Journal. 25(4). 56–56. 1 indexed citations

Le, Kha, et al.. (2023). PK/PD modeling to characterize placebo and treatment effect of omalizumab for chronic spontaneous urticaria. CPT Pharmacometrics & Systems Pharmacology. 12(6). 795–807. 4 indexed citations

Tang, Fei, Rebecca Kunder, Tom Chu, et al.. (2023). First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers. Clinical and Translational Science. 16(9). 1653–1666. 37 indexed citations

Henderson, Lindsay M., Tracy Staton, Fang Cai, et al.. (2023). A mechanistic PK/PD model to enable dose selection of the potent anti‐tryptase antibody (MTPS9579A) in patients with moderate‐to‐severe asthma. Clinical and Translational Science. 16(4). 694–703. 2 indexed citations

Braithwaite, Irene, Fang Cai, Jennifer Tom, et al.. (2021). Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial. Journal of Allergy and Clinical Immunology. 148(3). 783–789. 33 indexed citations

10.

Zhu, Rui, Ryan Owen, Justin Wilkins, et al.. (2021). Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps. Pulmonary Pharmacology & Therapeutics. 71. 102080–102080. 2 indexed citations

11.

Gevaert, Philippe, Theodore A. Omachi, Jonathan Corren, et al.. (2020). Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. Journal of Allergy and Clinical Immunology. 146(3). 595–605. 453 indexed citations breakdown →

12.

Staton, Tracy, Kun Peng, Ryan Owen, et al.. (2019). A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers. BMC Pulmonary Medicine. 19(1). 5–5. 27 indexed citations

13.

Simpson, Eric L., Carsten Flohr, Lawrence F. Eichenfield, et al.. (2018). Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). Journal of the American Academy of Dermatology. 78(5). 863–871.e11. 245 indexed citations

14.

Owen, Ryan, Li Gong, Hersh Sagreiya, Teri E. Klein, & Russ B. Altman. (2010). VKORC1 Pharmacogenomics Summary. Pharmacogenetics and Genomics. 20(10). 642–644. 71 indexed citations

15.

Owen, Ryan, Katrin Sangkuhl, Teri E. Klein, & Russ B. Altman. (2009). Cytochrome P450 2D6. Pharmacogenetics and Genomics. 19(7). 559–562. 99 indexed citations

16.

Owen, Ryan, Russ B. Altman, & Teri E. Klein. (2008). PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics. Human Mutation. 29(4). 456–460. 34 indexed citations

17.

Owen, Ryan, Teri E. Klein, & Russ B. Altman. (2007). The Education Potential of the Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB). Clinical Pharmacology & Therapeutics. 82(4). 472–475. 13 indexed citations

18.

Zammit, Stanley, Glyn Lewis, Anita Thapar, et al.. (2005). Phenotypic variation between parent–offspring trios and non-trios in genetic studies of schizophrenia. Journal of Psychiatric Research. 40(7). 622–626. 2 indexed citations

19.

Owen, Ryan, Leah L. Lagpacan, Travis R. Taylor, et al.. (2005). FUNCTIONAL CHARACTERIZATION AND HAPLOTYPE ANALYSIS OF POLYMORPHISMS IN THE HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER, ENT2. Drug Metabolism and Disposition. 34(1). 12–15. 30 indexed citations

20.

Owen, Ryan, Jennifer H. Gray, Travis R. Taylor, et al.. (2005). Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2. Pharmacogenetics and Genomics. 15(2). 83–90. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact